Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid for Blood Loss in Osteogenesis Imperfecta Surgery
NCT05321199Completed
- Sponsor
- Assiut University
- Start
- May 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of tranexamic acid in osteogenesis imperfecta (OI) (2 arms), sponsored by Assiut University. Primary endpoint: Percentage of change in mean blood loss. Started May 2022; status: completed.
02
Drugs
tranexamic acid
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT05321199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321199.